LVP vs TIPS for Refractory Ascites: Where Do We Stand?

Rakesh K. Varma; Karan Bir Singh; Eric Bready; Deepak Singh; Theresa M. Caridi; Mohamed Shoreibah

doi:10.1055/s-0042-1745863

Digestive Disease Interventions, Table of Contents

Digestive Disease Interventions 2022; 06(02): 086-093
DOI: 10.1055/s-0042-1745863

Review Article

LVP vs TIPS for Refractory Ascites: Where Do We Stand?

Rakesh K. Varma

¹Division of Interventional Radiology, University of Alabama at Birmingham, Alabama

,

Karan Bir Singh

²Department of Internal Medicine, Avalon University School of Medicine, Willemstad, Curacao

,

Eric Bready

¹Division of Interventional Radiology, University of Alabama at Birmingham, Alabama

,

Deepak Singh

³Caribbean Medical School, Caribbean Medical University, Willemstad, Curacao

,

Theresa M. Caridi

¹Division of Interventional Radiology, University of Alabama at Birmingham, Alabama

,

Mohamed Shoreibah

⁴Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Alabama

› Author Affiliations

Abstract

Ascites is the most common complication of end stage liver disease. Refractory ascites is considered a poor prognostic indicator and impacts quality of life, overall survival and contributes significantly to the cost associated with its management. Serial large volume paracentesis (LVP) and transjugular intrahepatic portosystemic shunt (TIPS) placement are the most utilized procedures for the management of refractory ascites and have their advantages and disadvantages. The pathophysiology of ascites in cirrhosis is multifactorial which makes management complex, requiring the consideration of multiple clinical and biochemical variables to guide the appropriate management. This article provides a broad overview of LVP and TIPS, with review of the latest clinical trials and meta-analyses to help guide the management of refractory ascites and improve patient outcomes.

Keywords

refractory ascites - large volume paracentesis - transjugular intrahepatic portosystemic shunt - cirrhosis - portal hypertension

Full Text

References

References
1 Sundaram V, Manne V, Al-Osaimi AM. Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol 2014; 20 (05) 279-287
2 Hsu SJ, Huang HC. Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc 2013; 76 (03) 123-130
3 Ennaifer R, Elleuch N, Romdhane H. et al. Prognosis of refractory ascites in cirrhosis. Tunis Med 2016; 94 (01) 12-15
4 Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49 (06) 2087-2107
5 Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol 2014; 20 (45) 16996-17010
6 Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20 (10) 2704-2714
7 Caly WR, Abreu RM, Bitelman B, Carrilho FJ, Ono SK. Clinical Features of Refractory Ascites in Outpatients. Clinics (São Paulo) 2017; 72 (07) 405-410
8 Madoff DC, Cornman-Homonoff J, Fortune BE. et al. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021; 298 (03) 493-504
9 Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330 (05) 337-342
10 Adams DH. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Gut 2007; 56 (08) 1175
11 Stanley MM, Ochi S, Lee KK. et al; Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 1989; 321 (24) 1632-1638
12 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015; 6 (03) 124-137
13 Pinchot JW, Kalva SP, Majdalany BS. et al; Expert Panels on Interventional Radiology and Vascular Imaging. ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension. J Am Coll Radiol 2021; 18 (5S): S153-S173
14 Runyon BA. AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57 (04) 1651-1653
15 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) 2017; 5 (02) 104-112
16 Kwan SW, Allison SK, Gold LS, Shin DS. Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data. J Vasc Interv Radiol 2018; 29 (12) 1705-1712
17 Khungar V, Saab S. Cirrhosis with refractory ascites: serial large volume paracentesis, TIPS, or transplantation?. Clin Gastroenterol Hepatol 2011; 9 (11) 931-935 , quiz e121–e122
18 Mallory A, Schaefer JW. Complications of diagnostic paracentesis in patients with liver disease. JAMA 1978; 239 (07) 628-630
19 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
20 Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55 (04) 1172-1181
21 Ginès A, Fernández-Esparrach G, Monescillo A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111 (04) 1002-1010
22 Sola-Vera J, Miñana J, Ricart E. et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37 (05) 1147-1153
23 Moreau R, Valla DC, Durand-Zaleski I. et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006; 26 (01) 46-54
24 Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21 (05) 525-529
25 Thomson A, Cain P, Kerlin P, Strong R. Serious hemorrhage complicating diagnostic abdominal paracentesis. J Clin Gastroenterol 1998; 26 (04) 306-308
26 Rösch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology 1969; 92 (05) 1112-1114
27 Colapinto RF, Stronell RD, Birch SJ. et al. Creation of an intrahepatic portosystemic shunt with a Grüntzig balloon catheter. Can Med Assoc J 1982; 126 (03) 267-268
28 Moore KP, Wong F, Gines P. et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38 (01) 258-266
29 Fejfar T, Safka V, Hůlek P, Vanásek T, Krajina A, Jirkovský V. [MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS]. Vnitr Lek 2006; 52 (09) 771-776
30 Salerno F, Merli M, Cazzaniga M. et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36 (04) 494-500
31 Angermayr B, Cejna M, Karnel F. et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52 (06) 879-885
32 Spengler EK, Hunsicker LG, Zarei S, Zimmerman MB, Voigt MD. Transjugular intrahepatic portosystemic shunt does not independently increase risk of death in high model for end stage liver disease patients. Hepatol Commun 2017; 1 (05) 460-468
33 Kamath PS, Wiesner RH, Malinchoc M. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (02) 464-470
34 Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol 2012; 35 (06) 1295-1300
35 Sterling KM, Darcy MD. Stenosis of transjugular intrahepatic portosystemic shunts: presentation and management. AJR Am J Roentgenol 1997; 168 (01) 239-244
36 Jung HS, Kalva SP, Greenfield AJ. et al. TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent-grafts. J Vasc Interv Radiol 2009; 20 (02) 180-185
37 Saad WE. The history and future of transjugular intrahepatic portosystemic shunt: food for thought. Semin Intervent Radiol 2014; 31 (03) 258-261
38 Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41 (02) 386-400
39 Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43 (06) 990-996
40 Fonio P, Discalzi A, Calandri M. et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med (Torino) 2017; 122 (09) 713-721
41 Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101 (06) 493-501
42 Mamiya Y, Kanazawa H, Kimura Y. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res 2004; 30 (03) 162-168
43 Morgan MY, Amodio P. Treatment for hepatic encephalopathy: tips from TIPS?. J Hepatol 2005; 42 (05) 626-628
44 Liu J, Wehrenberg-Klee EP, Bethea ED, Uppot RN, Yamada K, Ganguli S. Transjugular Intrahepatic Portosystemic Shunt Placement for Portal Hypertension: Meta-Analysis of Safety and Efficacy of 8 mm vs. 10 mm Stents. Gastroenterol Res Pract 2020; 2020: 9149065
45 Miraglia R, Maruzzelli L, Di Piazza A. et al. Transjugular Intrahepatic Portosystemic Shunt Using the New Gore Viatorr Controlled Expansion Endoprosthesis: Prospective, Single-Center, Preliminary Experience. Cardiovasc Intervent Radiol 2019; 42 (01) 78-86
46 Parvinian A, Bui JT, Knuttinen MG, Minocha J, Gaba RC. Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites. Diagn Interv Radiol 2014; 20 (01) 58-64
47 Trotter JF, Suhocki PV, Rockey DC. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am J Gastroenterol 1998; 93 (10) 1891-1894
48 Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96 (08) 2442-2447
49 Allegretti AS, Ortiz G, Cui J. et al. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016; 68 (03) 381-391
50 Deltenre P, Mathurin P, Dharancy S. et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25 (02) 349-356
51 Bureau C, Thabut D, Oberti F. et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. [published correction appears in Gastroenterology. 2017 Sep;153(3):870] Gastroenterology 2017; 152 (01) 157-163
52 Narahara Y, Kanazawa H, Fukuda T. et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46 (01) 78-85
53 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. [published correction appears in Gastroenterology. 2007 Nov;133(5):1746] Gastroenterology 2007; 133 (03) 825-834
54 Sanyal AJ, Genning C, Reddy KR. et al; North American Study for the Treatment of Refractory Ascites Group. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124 (03) 634-641
55 Ginès P, Uriz J, Calahorra B. et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123 (06) 1839-1847
56 Rössle M, Ochs A, Gülberg V. et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342 (23) 1701-1707
57 Lebrec D, Giuily N, Hadengue A. et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25 (02) 135-144
58 Salerno F, Merli M, Riggio O. et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40 (03) 629-635
59 Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; (04) CD004889
60 D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129 (04) 1282-1293
61 Rector Jr WG. Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986; 6 (04) 221-226
62 Morali GA, Sniderman KW, Deitel KM. et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 1992; 16 (1-2): 249-250
63 Bucsics T, Hoffman S, Grünberger J. et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int 2018; 38 (06) 1036-1044
64 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
65 Bureau C, Thabut D, Jezequel C. et al. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial. Ann Intern Med 2021; 174 (05) 633-640
66 Gülberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002; 66 (02) 127-130
67 Mattock R, Tripathi D, O'Neill F. et al. Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterol 2021; 8 (01) e000641
68 Campbell MS, Brensinger CM, Sanyal AJ. et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005; 42 (03) 635-640